Tucatinib
Phase 1Active 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic HER2+ Advanced Breast Cancer
Conditions
Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
Trial Timeline
Jun 29, 2022 → Dec 31, 2026
NCT ID
NCT05382364About Tucatinib
Tucatinib is a phase 1 stage product being developed by Pfizer for Metastatic HER2+ Advanced Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05382364. Target conditions include Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05892068 | Phase 2 | Active |
| NCT05382364 | Phase 1 | Active |
Competing Products
20 competing products in Metastatic HER2+ Advanced Breast Cancer